Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Genetics and Molecular Research

• Publication date

  2015-05-25

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4238/2015.May.25.15PMID 26125761
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma

  2012cited by this paper
• Leukemia stem cells

  2011cited by this paper
• Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.

  2011cited by this paper
• Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium study

  2010cited by this paper
• Leukemia stem cells.

  2010cited by this paper
• Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

  2010cited by this paper
• Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway.

  2009cited by this paper
• Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

  2009cited by this paper
• CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

  2009cited by this paper
• CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

  2009cited by this paper
• Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis

  2008cited by this paper
• Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell leukemia/lymphoma.

  2007cited by this paper
• Pediatric acute myeloid leukemia: towards high-quality cure of all patients

  2007cited by this paper
• Identification of side population cells (stem-like cell population) in pediatric solid tumor cell lines.

  2007cited by this paper
• CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia

  2007cited by this paper
• Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties

  2006cited by this paper
• Targeting of CD44 eradicates human acute myeloid leukemic stem cells

  2006cited by this paper
• Eradication of Leukemia Stem Cells as a New Goal of Therapy in Leukemia

  2006cited by this paper
• The SIRP family of receptors and immune regulation

  2006cited by this paper
• Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

  2006cited by this paper
• Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System

  2006cited by this paper
• Curing childhood acute myeloid leukemia (AML) at the half‐way point: Promises to keep and miles to go before we sleep

  2006cited by this paper
• Side Population Cells Derived from Adult Human Liver Generate Hepatocyte-like Cells In Vitro

  2005cited by this paper
• Cancer stem cells: lessons from leukemia.

  2005cited by this paper
• The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.

  2005cited by this paper
• Monoclonal antibody therapy of cancer.

  2005cited by this paper
• Mechanisms controlling pathogenesis and survival of leukemic stem cells

  2004cited by this paper
• Engraftment of Acute Myeloid Leukemia in NOD/SCID Mice Is Independent of CXCR4 and Predicts Poor Patient Survival

  2004cited by this paper
• Cancer Stem Cells Persist in Many Cancer Cell Lines

  2004cited by this paper
• Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML).

  2003cited by this paper
• Side-Population Cells from Different Precursor Compartments

  2003cited by this paper
• Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo

  2002cited by this paper
• Integrin-associated protein (CD47) and its ligands.

  2001cited by this paper
• The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells

  2000cited by this paper
• Monoclonal antibody therapy of cancer

  1999cited by this paper
• Integrin-associated Protein Is a Ligand for the P84 Neural Adhesion Molecule*

  1999cited by this paper
• Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo

  1996cited by this paper
• Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding

  1993cited by this paper
• Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1)

  1980cited by this paper

• CD47/HIF-1α circuit promotes cell proliferation in hepatocellular carcinoma.

  2025cites this paper
• RNA modification in normal hematopoiesis and hematologic malignancies

  2024cites this paper
• Emerging phagocytosis checkpoints in cancer immunotherapy

  2023influential citation
• [Molecular mechanisms of impaired antigenic presentation as a cause of tumor escape from immune surveillance].

  2023cites this paper
• Clinicopathological analysis of CD47 and signal regulatory protein alpha expression in myeloid sarcoma patients: CD47 expression is a favourable prognostic factor.

  2023cites this paper
• CYLD stimulates macrophage phagocytosis of leukemic cells through STAT1 signalling in acute myeloid leukemia

  2023cites this paper
• Present and Future Role of Immune Targets in Acute Myeloid Leukemia

  2022cites this paper
• Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes

  2022cites this paper
• Strategies and Applications for Improving the Stability of Black Phosphorus in Physical Environment

  2021cites this paper
• Preparation of Composite Cypate Nanoparticles and Its Application in the Treatment of Pediatric Bladder Tumors.

  2021cites this paper
• Black phosphorus-based photothermal therapy with aCD47-mediated immune checkpoint blockade for enhanced cancer immunotherapy

  2020cites this paper
• Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function

  2020cites this paper
• Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions.

  2020cites this paper
• CD47 antibody suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy.

  2020cites this paper
• Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies

  2020cites this paper
• The development of small-molecule inhibitors targeting CD47.

  2020cites this paper
• OTT_A_249822 9323..9331

  2020cites this paper
• Advances in Acute Myeloid Leukemia Stem Cells

  2019influential citation
• CD47 deficiency protects cardiomyocytes against hypoxia/reoxygenation injury by rescuing autophagic clearance.

  2019cites this paper
• OTT_A_223946 10597..10613

  2019influential citation
• Nucleic Acid Aptamer: A Novel Potential Diagnostic and Therapeutic Tool for Leukemia

  2019influential citation
• Advances in Acute Myeloid Leukemia Stem Cells

  2019influential citation
• Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.

  2018cites this paper
• CALR and CD47: An Insight into Their Roles in the Disease Progression of MDS and MPN

  2018cites this paper
• A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety.

  2018cites this paper
• Cancer-immune system interplay in the tumor microenvironment

  2017cites this paper
• The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer

  2017cites this paper
• “Eating” Cancer cells by blocking CD47 signaling: Cancer therapy by targeting the innate immune checkpoint

  2017cites this paper
• CD47 is not Over-Expressed in Fibrolamellar Hepatocellular Carcinoma.

  2017cites this paper
• Renewing the immunological approach to AML treatment: from novel pathways to innovative therapies

  2016cites this paper
• Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation

  2016cites this paper